Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT04882631 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants

Start date: April 12, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, single-arm, randomized, evaluator-blinded repeat insult patch testing (RIPT) study wherein test product is applied under an occlusive dressing to the upper back or arm continuously and repeatedly to the same site for a period of 21 days.

NCT ID: NCT04881955 Completed - Healthy Volunteer Clinical Trials

Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects

Start date: May 12, 2021
Phase: Phase 1
Study type: Interventional

Phase 1, single-center (United Kingdom), open-label, nonrandomized, single-dose study in healthy adult male subjects to assess the absorption, metabolism, and excretion of [14C]-Ecopipam in Healthy Male Subjects.

NCT ID: NCT04878471 Completed - Healthy Volunteers Clinical Trials

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

Start date: June 2, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single intravenous doses of ASP5354 in healthy, adult Japanese male participants.

NCT ID: NCT04878406 Completed - Clinical trials for Healthy Volunteers Type 2 Diabetes

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Start date: May 18, 2021
Phase: Phase 1
Study type: Interventional

This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese men when it is given together with semaglutide. Participants will get NNC0480-0389 and semaglutide or 2 doses of placebo - which treatment participants get is decided by chance. NNC0480-0389 is a new medicine that has not been previously approved. It means that the medicine has not yet been approved by the health authorities. Semaglutide is a newly approved antidiabetic medicine that helps to lower blood sugar levels in patients with type 2 diabetes. NNC0480-0389 is being developed to be given together with semaglutide.NNC0480-0389 targets a different part of the system that regulates sugar levels in the body than semaglutide. Therefore, it is expected that together NNC0480-0389 and semaglutide will more effectively lower sugar levels in the blood. Participants will get 2 injections of the study medicine. It will be injected with a needle into a skin fold on participants' stomach. The study will last for a maximum of 72 days. Participants will have 10 scheduled visits with the study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5 nights).The study includes blood sampling.

NCT ID: NCT04878315 Withdrawn - Healthy Volunteers Clinical Trials

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Start date: February 13, 2022
Phase: Phase 1
Study type: Interventional

This is a bioequivalence study to compare Capoten (test product [T]) versus captopril (reference product [R]) produced by Mylan Pharmaceuticals Spain, in healthy adult participants under fasting condition. Capoten is the registered trademark of SmithKline Beecham Egypt.

NCT ID: NCT04877769 Completed - Clinical trials for Healthy Volunteer Study

Bronchopulmonary PK of AT-527 (R07496998)

Start date: April 25, 2021
Phase: Phase 1
Study type: Interventional

This study will assess the safety, tolerability and bronchopulmonary pharmacokinetics (PK) of AT-527 (R07496998)

NCT ID: NCT04876807 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Start date: January 28, 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the effect of an acidic formulation of Acalabrutinib (ACP-196), acidic beverage, or grapefruit Juice on the PK of ACP-196 alone and coadministered with omeprazole.

NCT ID: NCT04868292 Completed - Healthy Volunteers Clinical Trials

Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers

Start date: June 3, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of SPR206 in healthy adult volunteers.

NCT ID: NCT04867980 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Start date: April 1, 2016
Phase: Phase 1
Study type: Interventional

This study is to evaluate the effects of single therapeutic and supratherapeutic oral doses of ACP-196 on the heart rate-corrected QT interval using Fridericia's formula (QTcF).

NCT ID: NCT04865445 Completed - Clinical trials for Healthy Volunteer Study

Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

Start date: April 22, 2021
Phase: Phase 1
Study type: Interventional

Drug-drug interaction study of midazolam and AT-527 (R07496998)